Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood

Volumn 129, Issue 5, 2017, Pages 553-560

  Grever, Michael R ^a   Abdel Wahab, Omar ^b   Andritsos, Leslie A ^a   Banerji, Versha ^c   Barrientos, Jacqueline ^d   Blachly, James S ^a   Call, Timothy G ^e   Catovsky, Daniel ^f   Dearden, Claire ^g   Demeter, Judit ^h   Else, Monica ^f   Forconi, Francesco ⁱ   Gozzetti, Alessandro ^j   Ho, Anthony D ^k   Johnston, James B ^c   Jones, Jeffrey ^a   Juliusson, Gunnar ^l   Kraut, Eric ^a   Kreitman, Robert J ^m   Larratt, Loree ⁿ   Lauria, Francesco ^j   Lozanski, Gerard ^o   Montserrat, Emili ^p   Parikh, Sameer A ^e   Park, Jae H ^b   Polliack, Aaron ^q   Quest, Graeme R ^r   Rai, Kanti R ^d   Ravandi, Farhad ^s   Robak, Tadeusz ^t   Saven, Alan ^u   Seymour, John F ^v   Tadmor, Tamar ^w   Tallman, Martin S ^b   Tam, Constantine ^v   Tiacci, Enrico ^x   Troussard, Xavier ^y   Zent, Clive S ^z   Zenz, Thorsten ^aa   Zinzani, Pier Luigi ^ab   Falini, Brunangelo ^x   more..

^a OHIO STATE UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d HOFSTRA UNIVERSITY   (United States)

^e MAYO CLINIC   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g Royal Marsden Cancer Centre   (United Kingdom)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY HOSPITAL OF SIENA   (Italy)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o OHIO STATE UNIVERSITY   (United States)

^p UNIVERSITY OF BARCELONA   (Spain)

^q HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^r UNIVERSITY HEALTH NETWORK   (Canada)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^t MEDICAL UNIVERSITY OF LODZ   (Poland)

^u SCRIPPS CLINIC   (United States)

^v UNIVERSITY OF MELBOURNE   (Australia)

^w TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^x SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^y CHU CÔTE DE NACRE   (France)

^z UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^aa GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ab UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE; VEMURAFENIB; ANTINEOPLASTIC AGENT;

CLASSIC HAIRY CELL LEUKEMIA; DISEASE COURSE; HAIRY CELL LEUKEMIA; HUMAN; INFECTION PREVENTION; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; LEUKEMIA, HAIRY CELL; NEOPLASM, RESIDUAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CLADRIBINE; DISEASE MANAGEMENT; HUMANS; LEUKEMIA, HAIRY CELL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PENTOSTATIN; TREATMENT OUTCOME;

EID: 85015285314     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-689422     Document Type: Review

References (80)

1. Gosselin GR, Hanlon DG, Pease GL. Leukaemic reticuloendotheliosis. Can Med Assoc J. 1956; 74(11): 886-891.
2. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7): 609-630.
3. Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: Update on molecular profiling and therapeutic advances. Blood Rev. 2014;28(5): 197-203.
4. Piris MA, Foucar K, Mollejo M, Campo E, Falini B. Splenic B-cell lymphoma/leukaemia, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC; 2008: 191-193.
5. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24): 2305-2315.
6. Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14): 3330-3332.
7. Chung SS, Kim E, Park JH, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014;6(238): 238ra71.
8. Pettirossi V, Santi A, Imperi E, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125(8): 1207-1216.
9. Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46(1): 8-10.
10. Arons E, Kreitman RJ. Molecular variant of hairy cell leukemia with poor prognosis. Leuk Lymphoma. 2011;52(Suppl 2): 99-102.
11. Forconi F, Cencini E, Sozzi E, Sicuranza A, Raspadori D, Lauria F. Insight into the behavior of hairy cell leukemia by immunogenetic analysis. Leuk Lymphoma. 2011;52(Suppl 2): 103-107.
12. Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-Agent cladribine and with more aggressive behavior. Blood. 2009; 114(21): 4696-4702.
13. Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ. Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood. 2011;117(18): 4844-4851.
14. Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-Term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014; 123(2): 177-183.
15. Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol. 2011;29(5): 583-590.
16. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long-Term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol. 1999; 106(2): 515-519.
17. Cornet E, Tomowiak C, Tanguy-Schmidt A, et al; Société Française d'Hématologie. Long-Term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol. 2014;166(3): 390-400.
18. Johnston JB, Eisenhauer E, Corbett WE, Scott JG, Zaentz SD. Efficacy of 29-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1988;80(10): 765-769.
19. Chandran R, Gardiner SK, Smith SD, Spurgeon SE. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol. 2013;163(3): 407-409.
20. Cornet E, Delmer A, Feugier P, et al; French Society of Haematology. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol. 2014;93(12): 1977-1983.
21. Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011; 118(14): 3818-3823.
22. Lauria F, Cencini E, Forconi F. Alternative methods of cladribine administration. Leuk Lymphoma. 2011;52(Suppl 2): 34-37.
23. von Rohr A, Schmitz SF, Tichelli A, et al; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol. 2002;13(10): 1641-1649.
24. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol. 1995;13(4): 989-995.
25. Sigal DS, Sharpe R, Burian C, Saven A. Very longterm eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010;115(10): 1893-1896.
26. Else M, Dearden CE, Matutes E, et al. Long-Term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6): 733-740.
27. Flinn IW, Kopecky KJ, Foucar MK, et al. Longterm follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000; 96(9): 2981-2986.
28. Juliusson G, Samuelsson H; Swedish Lymphoma Registry. Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-Term follow-up of subcutaneous therapy. Leuk Lymphoma. 2011;52(Suppl 2): 46-49.
29. Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens. Leuk Lymphoma. 2011;52(Suppl 2): 62-64.
30. Frassoldati A, Lamparelli T, Federico M, et al; Italian Cooperative Group for Hairy Cell Leukemia. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Leuk Lymphoma. 1994;13(3-4): 307-316.
31. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2): 50-52.
32. Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. 2011;136(4): 625-630.
33. Sandes AF, de Lourdes Chauffaille M, Oliveira CR, et al. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom. 2014;86(2): 98-105.
34. Pillai V, Pozdnyakova O, Charest K, Li B, Shahsafaei A, Dorfman DM. CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013;140(4): 536-543.
35. Sherman MJ, Hanson CA, Hoyer JD. An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. Am J Clin Pathol. 2011;136(3): 390-399.
36. Foucar K, Falini B, Catovsky D, Stein H. Hairy Cell Leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC; 2008.
37. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363(9424): 1869-1870.
38. Uppal G, Ly V, Wang ZX, et al. The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia. Am J Clin Pathol. 2015;143(1): 120-125.
39. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012; 36(12): 1796-1800.
40. Bailleux C, Robert G, Ginet C, et al. Successful re-Treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. Oncoscience. 2014;2(1): 44-49.
41. Blachly JS, Lozanski G, Lucas DM, Grever MR, Kendra K, Andritsos LA. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. J Natl Compr Canc Netw. 2015;13(1): 9-13.
42. Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370(3): 286-288.
43. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013;31(20): e351-e352.
44. Follows GA, Sims H, Bloxham DM, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol. 2013;161(1): 150-153.
45. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21): 2038-2040.
46. Tiacci E, Park JH, De Carolis L, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015;373(18): 1733-1747.
47. Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119(1): 192-195.
48. Golomb HM. Hairy cell leukemia: lessons learned in twenty-five years. J Clin Oncol. 1983;1(10): 652-656.
49. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D; British Committee for Standards in Haematology. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol. 2012;156(2): 186-195.
50. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alpha-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13(4): 974-982.
51. Golomb HM. Fifty years of hairy cell leukemia treatments. Leuk Lymphoma. 2011;52(Suppl 2): 3-5.
52. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16): 1117-1121.
53. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80(9): 2203-2209.
54. Andritsos LA, Dunavin N, Lozanski G, et al. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. Haematologica. 2015;100(1): e18-e20.
55. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1): 21-28.
56. Naik RR, Saven A. My treatment approach to hairy cell leukemia. Mayo Clin Proc. 2012;87(1): 67-76.
57. Habermann TM, Andersen JW, Cassileth PA, Bennett JM, Oken MM. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol. 1992;80(4): 466-471.
58. Dietrich S, Zenz T. BRAF inhibitor therapy in HCL. Best Pract Res Clin Haematol. 2015;28(4): 246-252.
59. Grever MR. Hairy cell: young living longer but not cured. Blood. 2014;123(2): 150-151.
60. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD41 lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83(10): 2906-2911.
61. Brown NA, Betz BL, Weigelin HC, Elenitoba-Johnson KS, Lim MS, Bailey NG. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia. Am J Clin Pathol. 2015;143(1): 89-99.
62. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011; 52(Suppl 2): 75-78.
63. Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, et al; Swiss Group for Clinical Cancer Research (SAKK). Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a longterm follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med. 2006; 130(3): 374-377.
64. Akarca AU, Shende VH, Ramsay AD, et al. BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol. 2013;162(6): 848-851.
65. Lauria F, Raspadori D, Benfenati D, Rondelli D, Pallotti A, Tura S. Biological markers and minimal residual disease in hairy cell leukemia. Leukemia. 1992;6(Suppl 4): 149-151.
66. Richards JM, Mick R, Latta JM, et al. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood. 1990;76(10): 1941-1945.
67. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-Term followup of the Northwestern University experience. Blood. 2005;106(1): 241-246.
68. Zinzani PL, Pellegrini C, Stefoni V, et al. Hairy cell leukemia: evaluation of the long-Term outcome in 121 patients. Cancer. 2010;116(20): 4788-4792.
69. Maurer H, Haas P, Wengenmayer T, Lübbert M, Duyster J, Zeiser R. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. Ann Hematol. 2014;93(8): 1439-1440.
70. Vergote V, Dierickx D, Janssens A, et al. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Ann Hematol. 2014;93(12): 2087-2089.
71. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-Agent ibrutinib. Blood. 2015;125(16): 2497-2506.
72. Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15): 1822-1828.
73. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood. 1999; 94(10): 3340-3348.
74. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res. 2013;19(22): 6313-6321.
75. Tadmor T. Purine analog toxicity in patients with hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2): 38-42.
76. Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b): 1350-1363.
77. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012; 156(10): 743-745.
78. Whitaker JA, Shanafelt TD, Poland GA, Kay NE. Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014;12(7): 440-450.
79. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109(9): 3672-3675.
80. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5): 891-896.